Annovis Bio FY 2023 net loss $56.2M; cash $5.8M; PD Phase III completed, AD top-line data expected April

Annovis Bio, Inc.

2024-Q1 EPS reported -$0.72

Net loss Q4 2023 $22.2M vs $7.7M YoY; FY net loss $56.2M vs $25.3M.
Cash and equivalents $5.8M as of Dec 31, 2023, down from $28.4M.
R&D expenses $38.8M for FY 2023, up from $16.5M, driven by AD and PD trial costs.
PD Phase III completed with 471 patients; AD Phase II/III fully enrolled (353 patients); top-line efficacy data expected in April 2024.
Appointed Andrew Walsh as VP Finance in December 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Annovis Bio, Inc. reported fourth quarter and full year 2023 results: net income $22.2 million.

Period: fourth quarter and full year 2023
Net income: $22.2 million
Result: reported results

Exact text from the filing

today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-042695

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.